Apollomics (APLM) Competitors $5.79 -0.10 (-1.71%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. PASG, CARA, LIAN, CGTX, FNCH, OVID, LGVN, PULM, RVPH, and MURAShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Passage Bio (PASG), Cara Therapeutics (CARA), LianBio (LIAN), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Ovid Therapeutics (OVID), Longeveron (LGVN), Pulmatrix (PULM), Reviva Pharmaceuticals (RVPH), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Passage Bio Cara Therapeutics LianBio Cognition Therapeutics Finch Therapeutics Group Ovid Therapeutics Longeveron Pulmatrix Reviva Pharmaceuticals Mural Oncology Apollomics (NASDAQ:APLM) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings. Does the MarketBeat Community believe in APLM or PASG? Passage Bio received 49 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 68.83% of users gave Passage Bio an outperform vote. CompanyUnderperformOutperformApollomicsOutperform Votes480.00% Underperform Votes120.00% Passage BioOutperform Votes5368.83% Underperform Votes2431.17% Does the media favor APLM or PASG? In the previous week, Passage Bio had 3 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for Passage Bio and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 beat Passage Bio's score of -0.02 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Passage Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is APLM or PASG more profitable? Apollomics' return on equity of 0.00% beat Passage Bio's return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Passage Bio N/A -72.53%-52.10% Which has preferable earnings and valuation, APLM or PASG? Passage Bio has lower revenue, but higher earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.22M5.38-$172.60MN/AN/APassage BioN/AN/A-$102.06M-$1.07-0.31 Do institutionals & insiders have more ownership in APLM or PASG? 19.1% of Apollomics shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 4.3% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate APLM or PASG? Apollomics presently has a consensus target price of $200.00, suggesting a potential upside of 3,261.34%. Passage Bio has a consensus target price of $7.50, suggesting a potential upside of 2,172.73%. Given Apollomics' higher probable upside, equities analysts plainly believe Apollomics is more favorable than Passage Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, APLM or PASG? Apollomics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. SummaryPassage Bio beats Apollomics on 7 of the 13 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.56M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.31%P/E RatioN/A6.9521.9417.82Price / Sales5.38231.01380.9497.68Price / CashN/A65.6738.2634.64Price / Book0.135.936.453.98Net Income-$172.60M$143.22M$3.22B$247.81M7 Day PerformanceN/A4.28%5.85%3.19%1 Month Performance-42.73%-13.11%-9.55%-7.70%1 Year Performance-87.39%-8.51%11.83%1.49% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics1.6951 of 5 stars$5.95+1.0%$200.00+3,261.3%-87.4%$6.56M$1.22M0.0045Positive NewsGap DownPASGPassage Bio2.4946 of 5 stars$0.35+3.0%$7.50+2,042.2%-71.3%$21.76MN/A-0.30130News CoverageCARACara Therapeutics3.5483 of 5 stars$4.75-1.0%$27.84+486.1%N/A$21.73M$7.14M-0.2380Stock SplitGap DownLIANLianBioN/A$0.20+0.1%N/A-31.0%$21.61MN/A-0.25110CGTXCognition Therapeutics2.5376 of 5 stars$0.35-2.0%$7.13+1,953.3%-79.8%$21.51MN/A-0.3620Gap DownFNCHFinch Therapeutics GroupN/A$13.16-2.5%N/A+480.4%$21.14M$110,000.00-1.49190OVIDOvid Therapeutics4.1352 of 5 stars$0.29+2.2%$3.03+953.6%-91.1%$20.46M$566,000.00-0.6160Gap UpLGVNLongeveron3.0289 of 5 stars$1.35-3.6%$8.67+542.0%-24.0%$20.15M$2.39M-0.2120News CoveragePULMPulmatrixN/A$5.52+2.2%N/A+217.6%$20.15M$7.81M-2.0920RVPHReviva Pharmaceuticals2.2846 of 5 stars$0.60+13.2%$10.00+1,566.7%-74.1%$20.07MN/A-0.545Upcoming EarningsNews CoverageMURAMural Oncology2.5875 of 5 stars$1.16+2.7%$13.00+1,020.7%-24.4%$19.98MN/A-0.13119Options VolumeGap Up Related Companies and Tools Related Companies Passage Bio Competitors Cara Therapeutics Competitors LianBio Competitors Cognition Therapeutics Competitors Finch Therapeutics Group Competitors Ovid Therapeutics Competitors Longeveron Competitors Pulmatrix Competitors Reviva Pharmaceuticals Competitors Mural Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
